AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06277804
Drug: LTC004 in Combination With Cyclophosphamide and Fludarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTC004 was given on day 1 and cyclophosphamide (250 mg/m2) in combination with fludarabine (25 mg/m2) was given on days 3 and 4 of each cycle, Q3W, until disease progression, withdrawn informed or intolerable
Trial: NCT05459493
Drug: TJAOA101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once enrolled, participants will be administrated TJAOA101
Trial: NCT04999631
Drug: Ethanol Solution
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT05956769
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection
Trial: NCT05583188
Drug: Standard of care neoadjuvant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients not eligible for neoadjuvant nivolumab plus chemotherapy will receive standard of care systemic therapy post-PEF ablation followed by resection.
Trial: NCT05054530
Drug: GMA106 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GMA106 solution for injection. Subjects in each cohort will receive a single injection of GMA106 or matching placebo under fasting conditions and at the following target dose levels.
Trial: NCT05054530
Drug: GMA106 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for GMA106
Trial: NCT00755066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intranasal spray
Trial: NCT05340153
Drug: Artemether-Lumefantrine Drug Combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine is formulated as tablets and will be provided in blister packs. Each tablet contains 20 mg artemether and 120 mg lumefantrine. Every pack has a picture showing how the drug should be given and contains 1 blister of 12 tablets. It will be administered each day as two, four, six or eight tablets depending on the weight of the child.
Trial: NCT05112666
Drug: other DOACs
RxNorm normalized name: Doans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
Trial: NCT05112666
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.
Trial: NCT04285320
Drug: Intravesical antibiotic instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:~* Amikacin-30 mg in 60 ml of sterile water~* Gentamycin-80mg in 60ml sterile water~* Tobramycin-80 mg in 100 ml of sterile water
Trial: NCT04935476
Drug: Placebo 85 mg PO BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet, twice daily for 21 days.
Trial: NCT05753059
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations placebo/placebo, bendroflumethiazide/placebo, amiloride/placebo, added to bumetanide on Days 0, 7, 14 and 21
Trial: NCT05753059
Drug: Amiloride
RxNorm normalized name: Amiloride
DrugBank: Amiloride (DB00594)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of amiloride/placebo, and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
Trial: NCT05753059
Drug: Bendroflumethiazide
RxNorm normalized name: Bendroflumethiazide
DrugBank: Bendroflumethiazide (DB00436)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This study will employ a randomized placebo-controlled, double-blind, double-dummy, crossover design testing combinations of bendroflumethiazide/placebo and bendroflumethiazide/amiloride added to bumetanide on Days 0, 7, 14 and 21
Trial: NCT05932446
Drug: LY3819469
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT04285320
Drug: Antibiotic oral suppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:~* Trimethoprim daily (100 mg)~* Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)~* Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (50 mg)~* Nitrofurantoin monohydrate/macrocrystals daily (100 mg)~* Cephalexin daily (125 mg)~* Cephalexin daily (250 mg)~* Fosfomycin every 10 days (3 grams)
Trial: NCT06026891
Drug: MG-K10/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MG-K10 Humanized Monoclonal Antibody Injection
Trial: NCT04894617
Drug: Lactose monohydrate
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose monohydrate two tablet daily for a total of 5 days.
Trial: NCT05305599
Drug: ZED1227
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZED1227 is a peptidomimetic designed to inhibit the activity of human tissue transglutaminase 2 (TG2).
Trial: NCT05305599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05984134
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 subjects will be randomly assigned to the placebo for 7 days
Trial: NCT06538623
Drug: Liposome Irinotecan Injection II combined with Oxaliplatin, Fluorouracil, Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposome Irinotecan: 60 mg/m², Oxaliplatin: 85 mg/m², Fluorouracil: 2400 mg/m², Leucovorin: 400 mg/m², every 3 weeks (Q3W), administered via hepatic arterial infusion (HAIC);
Trial: NCT06538623
Drug: Tegodor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegodor: 40 mg per dose, twice daily for seven days, every 3 weeks (Q3W), taken orally.
Trial: NCT05435378
Drug: Vitamin B3 100 MG Oral Tablet
RxNorm normalized name: vitamin B3 100 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the non surgical treatment and the oral hygiene instructions The systemically administered vitamin B3 capsules will then given to the patients under the previously mentioned dosage.
Trial: NCT05435378
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the non surgical treatment and the oral hygiene instructions The systemically administered placebo capsules will then given to the patients under the previously mentioned dosage.
Trial: NCT04767009
Drug: PD-1/PD-L1 inhibitors (alone or in combination with chemotherapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive PD-1/PD-L1 inhibitors for up to 2 years or until confirmed progression or unacceptable toxicity. PD-1/PD-L1 inhibitors will be administrated as an intravenous(IV) infusion.
Trial: NCT04590495
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant will either be given a placebo . After consumption of the study drug, the participant will wait for 120 minutes to allow for digestion and for CBD to begin taking effect. Next, individuals will undergo a driving simulation and all participants will drive the same course. The simulator presents the individual with real life driving scenarios and is equipped with screens, a steering wheel, signals, and pedals. The participant will be instructed to drive the course for 25-35 minutes. They will be instructed to follow normal driving rules. The simulation will include highway, suburban, rural, and urban driving scenarios which will incorporate turns, changes in speed, and avoidance of cars/pedestrians.
Trial: NCT01997268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corn Oil
Trial: NCT01997268
Drug: SC401B 2 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01997268
Drug: SC401B 4 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01997268
Drug: SC401B 6 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04600167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the control group will receive placebo once weekly for 12 weeks
Trial: NCT06249750
Drug: Immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy is currently a hot spot in the field of tumor research. Immune Checkpoint Inhibitor (ICI) is a monoclonal antibody designed to target the negative immunoregulatory pathway overexpressed in tumor cells, which can release the anti-tumor immunosuppressive signals and restore the killing of tumors by the immune cells, and thus exert anti-tumor effects. ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d.
Trial: NCT06249750
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recent studies have found that the combination of RTK inhibitors and ICIs can exert synergistic effects on different mechanisms, which can compensate for the deficiencies of single-agent RTK inhibitors and single-agent ICIs in the treatment of CRPC and become a potential novel therapeutic strategy for solid malignant tumors. RTK inhibitor regimen: Anlotinib, 12mg, po., d2\~15, q21d.
Trial: NCT04949438
Drug: AZD4831
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of AZD4831 administered with 240 mL of water after an overnight fast of at least 10 hours.
Trial: NCT04942275
Drug: Pre-therapeutic imaging test
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The radiopharmaceutical used for lung perfusion PET consists in human albumin macroaggregates labeled with Ga-68 (68Ga-MAA). 68Ga- MAA are administrated intravenously.
Trial: NCT05181007
Drug: Mefanamic Acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mefanamic acid once every 6 hours on Day 4 and Day 5, Ciprofol on Day 1 and Day 5
Trial: NCT05157100
Drug: Ingrezza Pill
RxNorm normalized name: Ingrezza Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Ingrezza 40 mg and 80 mg tablets for 12 weeks.
Trial: NCT06423235
Drug: regular dose of JiRui® Prunella oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 10ml twice a day
Trial: NCT06423235
Drug: 2x regular dose of JiRui® Prunella oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 20ml twice a day
Trial: NCT06423235
Drug: regular dose of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 10ml twice a day
Trial: NCT06423235
Drug: 2x regular dose of placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take 20ml twice a day
Trial: NCT05047991
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil (5-Fu), intravenously, over 46 h on day 1 and day 15 of every 28-day cycle
Trial: NCT05047991
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin (LV), intravenously, over 30 min on day 1 and day 15 of every 28-day cycle
Trial: NCT05749081
Drug: Placebo in combination with vonorazan dual therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
Trial: NCT05186467
Drug: intraperitoneal Magnesium sulfate
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (IP) group will receive 100 ml normal saline infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline intraoperatively then intraperitoneal wash of 100 ml normal saline containing 30 mg/kg MgSO4 at the end of laparoscopy.
Trial: NCT05186467
Drug: intravenous magnesium sulfate
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) group will receive 100 ml normal saline containing MgSO4 30 mg/kg infused over 10 min immediately before the induction of anesthesia and then continuous infusion of 500 ml normal saline containing MgSO4 (8mg/kg) intraoperatively then intraperitoneal wash using 100 ml normal saline at the end of laparoscopy.
Trial: NCT05091528
Drug: SBT6050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles
Trial: NCT05091528
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 PO BID for 14 days of each 21-day cycle
Trial: NCT05052229
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide gas for inhalation
Trial: NCT03906318
Drug: Iticitinib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04996303
Drug: Routine steroid administration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid administration with routine dose - Methylprednisolone 1 mg/kg 7 days → 0.5 mg/kg 7 days → 0.25 mg kg 7 days
Trial: NCT05724602
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of placebo + IMRT followed by 3 cycles of placebo as monotherapy
Trial: NCT06663176
Drug: RESP302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitric Oxide agent
Trial: NCT06663176
Drug: RESP303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitric Oxide agent
Trial: NCT06444620
Drug: DTG/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a fixed-dose combined DTG/3TC pill each containing 50mg of dolutegravir and 300mg of lamivudine
Trial: NCT05002946
Drug: SP-104
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose
Trial: NCT05567731
Drug: long GnRHa
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the long protocol, daily subcutaneuous injection of Triptorelin :Decapeptyl 0.1 mg (Ferring, Switzerland) 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering. Gn stimulation started after fulfilling stimulation start criteria of thin endometrium \< 5 mm and low estradiol (E2) \< 50 and Luteinizing Hormone \< 5IU/l with either HMG(Menogon; Ferring, Switzerland) or rFSH (Gonal-f; Merck Serono, Germany) in a starting dose of 150-300 IU/day according to women age, day 3 Follicle-Stimulating Hormone, Anti-Müllerian Hormone and previous gonadotropin response then adjustment of the dose according to ovarian response monitored by serum estradiol (E2) and ultrasound evaluation.
Trial: NCT05525819
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cases will be subjected to spinal anesthesia with a 3 ml volume (2.5 ml of hyperbaric bupivacaine 10 mg in addition to 0.5 normal saline). 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
Trial: NCT05525819
Drug: Intrathecal group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The cases will be subjected to the same anesthetic mixture as controls with adding dexmedetomidine 5 μg in the saline component. 50 ml of normal saline was infused over a ten-minute period, followed by 200 ml infusion till the end of operation.
Trial: NCT05525819
Drug: Intravenous group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intravenous group will receive 2.5 ml of hyperbaric bupivacaine (10 mg), in addition to intravenous dexmedetomidine, which will be started at 1 μg/kg loading dose diluted in 50 ml saline administered within 10 min, followed by maintenance at a 0.4 μg/kg/h dose diluted in 200 ml saline till the end of the procedure.
Trial: NCT05028374
Drug: A single booster dose of the Moderna mRNA COVID-19 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.
Trial: NCT05118841
Drug: ZX-4081
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily (BID), oral dosing of ZX-4081 at the assigned dose level in a 28-day cycle
Trial: NCT05837104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, three times daily for four weeks.
Trial: NCT05649605
Drug: Testosterone treatment
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross-sex hormone therapy consisting of intramuscular injection of testosterone undecanoate 250mg/ml. 4ml (total dosage of 1000mg) administered by trained nurse in the gluteal region at visit 1.
Trial: NCT05407961
Drug: LY3532226
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05407961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05022810
Drug: New Paracetamol Oral Suspension (24 mg/ml)
RxNorm normalized name: New Day Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an overnight fasting for at least 10 hours, New Paracetamol Oral Suspension (24 mg/ml) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
Trial: NCT05022810
Drug: Panadol B&I Oral Suspension (24 mg/ml paracetamol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an overnight fasting for at least 10 hours, Panadol B\&I Oral Suspension (24 mg/ml paracetamol) in a volume of 42 ml will be administered orally via a single use syringe by a trained study person to the study participants as per the randomization schedule in each period.
Trial: NCT06506539
Drug: Placental Extract
RxNorm normalized name: human placental tissue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: add placental extract gel as a local delivery drug in periodontal pocket
Trial: NCT06508359
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prophylactic or rescue norepinephrine for spinal anesthesia-induced hypotension
Trial: NCT06176508
Drug: HS-10374-matched placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally QD for 16 weeks
Trial: NCT05198791
Drug: Stratified medicine - Microvascular dysfunction and eplerenone therapy, tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified medicine including interventional diagnostic procedure (IDP) and linked treatment with eplerenone. Patients with an increased IMR (strata with microvascular dysfunction, IMR ≥25) will be eligible for randomization to this arm. Patients randomized to receive eplerenone will be commenced on 25 mg once daily, and uptitrated to 50 mg once daily after two weeks. Treatment will be continued for a period of six months.
Trial: NCT01420666
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 325 mg, three tablets four times a day, orally, with food
Trial: NCT01420666
Drug: Maxigesic 325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
Trial: NCT01420666
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 97.5mg, three tablets four times a day, orally, with food
Trial: NCT01420666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, three tablets four times a day, orally, with food
Trial: NCT04708327
Drug: STAT-205
RxNorm normalized name: zinc oxide 0.205 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naltrexone hydrochloride capsules 4.5 mg each
Trial: NCT05475184
Drug: JPI-547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Poly-(ADP-ribose) polymerase (PARP) \& tankyrase (TNKS) inhibitor.~* The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.~* 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal.
Trial: NCT05052619
Drug: Preventive use of advanced antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treat patients in this group with advanced preventive usage of antibiocs: Sulperazon 3g q8h, in postoperative days 1-5.
Trial: NCT06267638
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intraoperative normal saline during total knee arthroplasty
Trial: NCT04874506
Drug: MBM-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug will be administered orally using the capsule formulation (200 mg). The study drug will be administered 7 days a week for the entire treatment period.
Trial: NCT05402995
Drug: Irrisept (Irrigation Solution)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrisept Antimicrobial Wound Lavage is intended for mechanical cleansing and removal of debris, dirt and foreign materials, including microorganisms from wounds.